Shi-Yong Sun Selected Research

TNF-Related Apoptosis-Inducing Ligand Receptors

1/2021	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
12/2015	Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.
1/2012	Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
8/2011	Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.
5/2011	Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
1/2011	Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis.
8/2010	Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact.
11/2008	Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
7/2008	CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
11/2007	CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shi-Yong Sun Research Topics

Disease

109	Neoplasms (Cancer) 11/2022 - 01/2002
42	Lung Neoplasms (Lung Cancer) 11/2022 - 01/2002
37	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2002
11	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2007
9	Carcinogenesis 01/2019 - 01/2002
9	Squamous Cell Carcinoma of Head and Neck 01/2016 - 09/2005
7	Multiple Myeloma 10/2018 - 12/2005
5	Colonic Neoplasms (Colon Cancer) 10/2011 - 01/2004
4	Head and Neck Neoplasms (Head and Neck Cancer) 08/2012 - 09/2009
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 12/2014
3	Adenocarcinoma of Lung 03/2019 - 01/2008
3	Prostatic Neoplasms (Prostate Cancer) 01/2014 - 07/2005
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021 - 01/2019
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 04/2010
2	Thyroid Neoplasms (Thyroid Cancer) 01/2019 - 04/2013
2	Necrosis 01/2019 - 04/2013
2	Adenocarcinoma 01/2019 - 09/2012
2	Glioblastoma (Glioblastoma Multiforme) 07/2013 - 02/2012
2	Lymphatic Metastasis 04/2013 - 01/2011
2	Rhabdomyosarcoma 01/2012 - 05/2011
2	Breast Neoplasms (Breast Cancer) 05/2011 - 01/2002

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2002
18	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2021 - 10/2004
17	osimertinibIBA 01/2022 - 10/2016
17	LigandsIBA 01/2021 - 12/2004
16	ErbB Receptors (EGF Receptor)IBA 10/2021 - 09/2005
14	TOR Serine-Threonine KinasesIBA 03/2019 - 08/2005
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 01/2006
12	MTOR InhibitorsIBA 04/2021 - 11/2007
11	Death Domain ReceptorsIBA 01/2021 - 12/2004
11	Sirolimus (Rapamycin)FDA Link 01/2019 - 08/2005
9	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2021 - 12/2008
9	Phosphotransferases (Kinase)IBA 01/2019 - 10/2004
9	Caspase 8 (Caspase-8)IBA 01/2017 - 10/2007
8	Tyrosine Kinase InhibitorsIBA 01/2022 - 10/2016
8	Pharmaceutical PreparationsIBA 01/2020 - 12/2006
7	Everolimus FDA Link 01/2019 - 08/2010
7	Proteasome InhibitorsIBA 10/2018 - 01/2006
7	Celecoxib (Celebrex)FDA Link 10/2011 - 12/2004
6	Mechanistic Target of Rapamycin Complex 1IBA 04/2021 - 09/2012
6	Eukaryotic Initiation Factor-4EIBA 04/2021 - 11/2007
6	RetinoidsIBA 08/2011 - 01/2002
6	TriterpenesIBA 09/2008 - 01/2002
5	Proteasome Endopeptidase Complex (Proteasome)IBA 10/2018 - 12/2006
5	Bortezomib (Velcade)FDA Link 05/2014 - 01/2006
5	bardoxolone methylIBA 09/2008 - 01/2002
4	Biological ProductsIBA 01/2022 - 07/2008
4	Deoxyglucose (2 Deoxy D glucose)IBA 04/2021 - 04/2008
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 12/2008
4	DNA (Deoxyribonucleic Acid)IBA 04/2015 - 10/2011
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2009 - 12/2004
3	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 11/2022 - 01/2019
3	B7-H1 AntigenIBA 10/2021 - 01/2019
3	Biomarkers (Surrogate Marker)IBA 08/2021 - 04/2013
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2019 - 09/2008
3	Glycogen Synthase (Synthase I)IBA 01/2019 - 10/2011
3	Mechanistic Target of Rapamycin Complex 2IBA 01/2019 - 10/2013
3	Peptide Initiation Factors (Initiation Factor)IBA 03/2012 - 08/2009
3	TNF-Related Apoptosis-Inducing LigandIBA 12/2011 - 12/2004
3	perifosineIBA 12/2010 - 07/2007
3	Docetaxel (Taxotere)FDA Link 08/2010 - 04/2007
3	UbiquitinIBA 05/2010 - 12/2006
3	CCAAT-Enhancer-Binding ProteinsIBA 07/2008 - 06/2007
3	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)IBA 11/2007 - 12/2006
3	Farnesyltranstransferase (Farnesyltransferase)IBA 06/2007 - 11/2004
2	AZD 6244IBA 01/2021 - 10/2016
2	Mitogen-Activated Protein KinasesIBA 01/2021 - 12/2005
2	RNA (Ribonucleic Acid)IBA 01/2021 - 04/2015
2	PanobinostatIBA 01/2020 - 04/2010
2	Histone Deacetylase InhibitorsIBA 01/2020 - 04/2010
2	carfilzomibIBA 10/2018 - 07/2015
2	TNF Receptor-Associated Factor 2 (TRAF2)IBA 01/2017 - 12/2015
2	Apoptosis Regulatory ProteinsIBA 01/2017 - 12/2015
2	binimetinibIBA 10/2016 - 08/2015
2	Messenger RNA (mRNA)IBA 01/2016 - 10/2013
2	Cetuximab (Erbitux)FDA Link 12/2014 - 07/2009
2	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2014 - 12/2011
2	Cisplatin (Platino)FDA LinkGeneric 12/2014 - 07/2009
2	NVP-BKM120IBA 09/2013 - 12/2012
2	Antineoplastic Agents (Antineoplastics)IBA 09/2013 - 01/2008
2	epidermal growth factor receptor VIIIIBA 07/2013 - 02/2012
2	Therapeutic UsesIBA 12/2012 - 04/2005
2	CytokinesIBA 12/2011 - 05/2007
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2011 - 12/2004
2	dactolisibIBA 09/2011 - 01/2011
2	SurvivinIBA 04/2010 - 11/2008
2	Small Interfering RNA (siRNA)IBA 04/2010 - 10/2007
2	NF-kappa B (NF-kB)IBA 09/2008 - 07/2005
2	honokiolIBA 07/2008 - 04/2007
2	PPAR gammaIBA 01/2008 - 01/2007
2	lonafarnib (SCH 66336)IBA 06/2007 - 11/2004
2	AndrogensIBA 04/2007 - 07/2005
2	naphthaleneIBA 07/2005 - 04/2002
2	Carboxylic AcidsIBA 07/2005 - 04/2002
2	CaspasesIBA 04/2002 - 01/2002

Therapy/Procedure

39	Therapeutics 01/2022 - 01/2002
6	Chemoprevention 01/2008 - 01/2002
2	Immunotherapy 01/2020 - 01/2019
2	Drug Therapy (Chemotherapy) 12/2014 - 04/2008
2	Radiotherapy 10/2011 - 04/2008